Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Upgraded by DZ Bank to “Hold” Rating

DZ Bank upgraded shares of Bayer Aktiengesellschaft (OTCMKTS:BAYRY) from a strong sell rating to a hold rating in a research report report published on Thursday morning,Zacks.com reports.

Other research analysts have also issued research reports about the company. Zacks Research lowered Bayer Aktiengesellschaft from a “hold” rating to a “strong sell” rating in a research report on Tuesday, March 24th. UBS Group raised Bayer Aktiengesellschaft from a “neutral” rating to a “buy” rating in a report on Monday, March 16th. Finally, Barclays upgraded shares of Bayer Aktiengesellschaft from an “equal weight” rating to an “overweight” rating in a research report on Tuesday, January 6th. Two equities research analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Bayer Aktiengesellschaft has an average rating of “Moderate Buy”.

Bayer Aktiengesellschaft Price Performance

Shares of OTCMKTS:BAYRY opened at $11.75 on Thursday. Bayer Aktiengesellschaft has a 12 month low of $5.70 and a 12 month high of $14.85. The firm has a market capitalization of $46.18 billion, a P/E ratio of -10.59 and a beta of 0.70. The company has a debt-to-equity ratio of 1.10, a current ratio of 1.14 and a quick ratio of 0.71. The company’s fifty day moving average price is $12.03 and its 200 day moving average price is $10.44.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last issued its quarterly earnings data on Wednesday, March 4th. The company reported $0.18 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.18. Bayer Aktiengesellschaft had a positive return on equity of 15.35% and a negative net margin of 8.51%.The company had revenue of $13.24 billion for the quarter, compared to analyst estimates of $13.08 billion. Bayer Aktiengesellschaft has set its FY 2026 guidance at 1.251-1.400 EPS. As a group, sell-side analysts predict that Bayer Aktiengesellschaft will post 1.31 earnings per share for the current fiscal year.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft is a global life sciences company headquartered in Leverkusen, Germany, with a history dating back to 1863. The company operates across three principal business areas—Pharmaceuticals, Consumer Health and Crop Science—serving customers and markets worldwide. Bayer develops, manufactures and markets prescription medicines, over-the-counter healthcare products and agricultural solutions, and maintains research and development programs focused on new therapies and technologies in its core fields.

In Pharmaceuticals, Bayer focuses on prescription drugs across therapeutic areas such as cardiology, oncology, hematology and women’s health, supporting clinical development and regulatory activities for both marketed products and pipeline candidates.